- ROUNDTABLE: Pharmacy’s future in sync with technology
- Senate passes Drug Quality and Security Act
- EXPERT BLOG: Provider status for pharmacists — one way or another
- Study from NCPA sheds new light on med synchronization programs
- Coalition of healthcare industry stakeholders address best practices regarding controlled substances
ALEXANDRIA, Va. — The National Community Pharmacists Association on Thursday reiterated its stance on compounding to the House Energy and Commerce Committee of the U.S. House of Representatives.
The House committee has conducted an investigation and held several hearings into how the meningitis outbreak was handled by the Food and Drug Administration and state regulators and, as Congress returns from its August recess, the panel is actively considering what policy or legislative changes may be necessary to avoid a similar public health crisis from happening again, NCPA reported.
“Compounding is the backbone of pharmacy practice and for many decades independent community pharmacists have provided millions of adults, children and animals with access to safe, effective and affordable medications through compounding services,” Hoey wrote to committee chairman Reps. Fred Upton, R-Mich., and ranking member Henry Waxman, D-Calif. “Compounding can help bridge the gaps during times of drug shortages. Drug shortages have nearly tripled, according to the FDA, and their impact can be devastating.”
NCPA expressed its dissent of a Senate proposal (S. 959) as currently written because it would inadvertently “create unnecessary federal regulatory burdens, hamper independent community pharmacies from providing medications to patients with unique health needs, and far exceeds a targeted approach to prevent another tragedy such as NECC.” Specifically, S. 959 would require community pharmacies to report directly to the FDA when they are compounding medications to alleviate a drug shortage. In addition, S. 959 would jeopardize patient access to vital medications by directing the FDA to maintain a “do not compound” list which could potentially be used by the agency to prevent compounding in response to a doctor’s prescription for medications such as hormone medications, thyroid preparations, promethazine gels and medications to treat autism, NCPA suggested.
Instead, NCPA supports the efforts of Rep. Morgan Griffith, R-Va., to develop bipartisan House legislation based on the “discussion draft” legislation posted on the committee’s website. The proposal “rightfully maintains state board of pharmacy oversight of traditional compounding pharmacies while strengthening badly needed two-way communications between the FDA and state boards of pharmacy.” Poor coordination and communication between FDA and state boards of pharmacy were a vital factor that prevented regulators from stopping or mitigating the impact of the meningitis outbreak, NCPA noted. Other provisions in the legislation would protect patient access to essential medications from pharmacies at hospitals and physician’s offices, yet clarify the authority of FDA and other regulators to go after any bad actors, such as the New England Compounding Center.
Get connected and follow us on LinkedIn for the most in-depth coverage of drug store news. Join the conversation.